Session Details
[1-NG]Frontiers of Ketamine, Psilocybin, and Next-Generation Psychedelic Research
Mon. Mar 16, 2026 10:10 AM - 11:40 AM JST
Mon. Mar 16, 2026 1:10 AM - 2:40 AM UTC
Mon. Mar 16, 2026 1:10 AM - 2:40 AM UTC
Room 3(B200)
Chair:Daisuke Ibi(Department of Chemical Pharmacology, Meijo University), Ichiro Kawahata(Fukushima Medical University)
This symposium will provide a comprehensive overview of cutting-edge research on novel antidepressants, including ketamine and psilocybin, which are considered to be breakthrough treatments for depression. Experts from a variety of fields will present the latest findings on molecular and cellular mechanisms, neural circuit and advances in drug development. The program aims to highlight the current challenges and future perspectives of translating basic research into clinical applications. This symposium will foster active discussion among researchers and hopefully serve as a platform to uncover the therapeutic potential of these innovative antidepressants. We hope it will inspire new ideas, promote interdisciplinary collaboration, and contribute to the development of next-generation treatments for depression.
[1-NG-01]Challenges and Future Strategies in Antidepressant Drug Discovery: DSP-3456, an mGluR2/3 Negative Allosteric Modulator, Paving the Way
*Kenichi Fukumoto1 (1. Sumitomo Pharma Co., Ltd.)
[1-NG-02]The antidepressant effects of serotonergic psychedelics: similarities and differences with ketamine
*Daisuke Ibi1 (1. Department of Chemical Pharmacology, Meijo University)
[1-NG-03]Common pallidal structural remodeling shared across diverse antidepressants revealed by mouse structural MRI
*Yoshifumi Abe1 (1. Keio University School of Medicine)
[1-NG-04]Molecular mechanisms underlying the sustained antidepressant actions of ketamine metabolites
*Shusaku Uchida1 (1. Institute of Science Tokyo)